Evolución del título de anticuerpos contra el receptor tipo M de la fosfolipasa A2 y respuesta clínica en pacientes con nefropatía membranosa idiopática tratados con tacrolimus
Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus
Leído
17739
Vecesse ha leído el artículo
3307
Total PDF
14432
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 52 | 44 | 96 |
| 2025 5 | 97 | 38 | 135 |
| 2025 4 | 80 | 22 | 102 |
| 2025 3 | 132 | 59 | 191 |
| 2025 2 | 107 | 36 | 143 |
| 2025 1 | 106 | 46 | 152 |
| 2024 12 | 80 | 33 | 113 |
| 2024 11 | 67 | 51 | 118 |
| 2024 10 | 77 | 37 | 114 |
| 2024 9 | 76 | 24 | 100 |
| 2024 8 | 79 | 46 | 125 |
| 2024 7 | 83 | 30 | 113 |
| 2024 6 | 88 | 45 | 133 |
| 2024 5 | 108 | 42 | 150 |
| 2024 4 | 88 | 41 | 129 |
| 2024 3 | 66 | 35 | 101 |
| 2024 2 | 76 | 25 | 101 |
| 2024 1 | 75 | 30 | 105 |
| 2023 12 | 63 | 24 | 87 |
| 2023 11 | 90 | 40 | 130 |
| 2023 10 | 74 | 32 | 106 |
| 2023 9 | 86 | 34 | 120 |
| 2023 8 | 68 | 27 | 95 |
| 2023 7 | 86 | 38 | 124 |
| 2023 6 | 59 | 17 | 76 |
| 2023 5 | 85 | 37 | 122 |
| 2023 4 | 59 | 21 | 80 |
| 2023 3 | 100 | 29 | 129 |
| 2023 2 | 84 | 28 | 112 |
| 2022 1 | 70 | 21 | 91 |
| 2022 12 | 76 | 30 | 106 |
| 2022 11 | 105 | 47 | 152 |
| 2022 10 | 123 | 41 | 164 |
| 2022 9 | 98 | 51 | 149 |
| 2022 8 | 89 | 48 | 137 |
| 2022 7 | 104 | 49 | 153 |
| 2022 6 | 104 | 53 | 157 |
| 2022 5 | 120 | 34 | 154 |
| 2022 4 | 132 | 53 | 185 |
| 2022 3 | 112 | 56 | 168 |
| 2022 2 | 125 | 58 | 183 |
| 2021 1 | 129 | 46 | 175 |
| 2021 12 | 93 | 44 | 137 |
| 2021 11 | 96 | 46 | 142 |
| 2021 10 | 94 | 47 | 141 |
| 2021 9 | 79 | 55 | 134 |
| 2021 8 | 74 | 37 | 111 |
| 2021 7 | 89 | 42 | 131 |
| 2021 6 | 108 | 36 | 144 |
| 2021 5 | 128 | 50 | 178 |
| 2021 4 | 230 | 124 | 354 |
| 2021 3 | 116 | 41 | 157 |
| 2021 2 | 110 | 30 | 140 |
| 2020 1 | 77 | 35 | 112 |
| 2020 12 | 84 | 40 | 124 |
| 2020 11 | 65 | 38 | 103 |
| 2020 10 | 64 | 28 | 92 |
| 2020 9 | 70 | 19 | 89 |
| 2020 8 | 49 | 28 | 77 |
| 2020 7 | 36 | 15 | 51 |
| 2020 6 | 50 | 23 | 73 |
| 2020 5 | 72 | 20 | 92 |
| 2020 4 | 95 | 34 | 129 |
| 2020 3 | 77 | 19 | 96 |
| 2020 2 | 71 | 19 | 90 |
| 2020 1 | 76 | 19 | 95 |
| 2019 12 | 73 | 35 | 108 |
| 2019 11 | 84 | 23 | 107 |
| 2019 10 | 61 | 18 | 79 |
| 2019 9 | 76 | 21 | 97 |
| 2019 8 | 71 | 13 | 84 |
| 2019 7 | 48 | 17 | 65 |
| 2019 6 | 72 | 32 | 104 |
| 2019 5 | 71 | 24 | 95 |
| 2019 4 | 126 | 45 | 171 |
| 2019 3 | 59 | 25 | 84 |
| 2019 2 | 46 | 25 | 71 |
| 2019 1 | 49 | 24 | 73 |
| 2018 12 | 152 | 52 | 204 |
| 2018 11 | 168 | 24 | 192 |
| 2018 10 | 134 | 11 | 145 |
| 2018 9 | 159 | 18 | 177 |
| 2018 8 | 89 | 20 | 109 |
| 2018 7 | 78 | 38 | 116 |
| 2018 6 | 90 | 14 | 104 |
| 2018 5 | 81 | 11 | 92 |
| 2018 4 | 79 | 12 | 91 |
| 2018 3 | 76 | 13 | 89 |
| 2018 2 | 55 | 8 | 63 |
| 2018 1 | 63 | 10 | 73 |
| 2017 12 | 75 | 6 | 81 |
| 2017 11 | 66 | 16 | 82 |
| 2017 10 | 65 | 10 | 75 |
| 2017 9 | 88 | 11 | 99 |
| 2017 8 | 97 | 21 | 118 |
| 2017 7 | 120 | 8 | 128 |
| 2017 6 | 127 | 10 | 137 |
| 2017 5 | 125 | 16 | 141 |
| 2017 4 | 112 | 17 | 129 |
| 2017 3 | 97 | 23 | 120 |
| 2017 2 | 136 | 31 | 167 |
| 2016 1 | 60 | 11 | 71 |
| 2016 12 | 151 | 24 | 175 |
| 2016 11 | 155 | 13 | 168 |
| 2016 10 | 210 | 44 | 254 |
| 2016 9 | 295 | 9 | 304 |
| 2016 8 | 349 | 7 | 356 |
| 2016 7 | 341 | 10 | 351 |
| 2016 6 | 213 | 0 | 213 |
| 2016 5 | 255 | 0 | 255 |
| 2016 4 | 183 | 0 | 183 |
| 2016 3 | 164 | 0 | 164 |
| 2016 2 | 216 | 0 | 216 |
| 2015 1 | 195 | 0 | 195 |
| 2015 12 | 220 | 0 | 220 |
| 2015 11 | 192 | 0 | 192 |
| 2015 10 | 195 | 0 | 195 |
| 2015 9 | 163 | 0 | 163 |
| 2015 8 | 160 | 0 | 160 |
| 2015 7 | 173 | 0 | 173 |
| 2015 6 | 110 | 0 | 110 |
| 2015 5 | 212 | 0 | 212 |
| 2015 4 | 60 | 0 | 60 |
| 2015 2 | 1111 | 0 | 1111 |
Mostrar todo
